COVID-19与凝血:SARS-CoV-2感染的出血与血栓表现
这项多中心回顾性研究描述了400例住院COVID-19患者(144例危重症)的止血与血栓并发症发生率及严重程度,患者主要接受标准剂量预防性抗凝。影像学确诊静脉血栓栓塞率为4.8%,总体血栓并发症率为9.5%,总体出血率4.8%,大出血率2.3%。初始D-二聚体升高可预测住院期间凝血相关并发症、危重症和死亡。
要点
- 住院COVID-19患者影像学确诊VTE率为4.8%,总体血栓并发症率为9.5%。
- 初始D-二聚体>2500 ng/mL与血栓并发症调整OR 6.79、出血调整OR 3.56相关。
- DIC、临床相关血小板减少和纤维蛋白原降低少见,且与明显出血表现相关。
核心结论
- 住院COVID-19患者中血栓与出血并发症均可发生,初始D-二聚体升高可预测凝血相关并发症、危重症和死亡。
- 鉴于观察到的出血率,需要随机试验来确定COVID-19患者强化抗凝预防是否有潜在获益。
研究设计与样本
- 多中心回顾性研究,纳入400例住院COVID-19患者,其中144例为危重症,主要接受标准剂量预防性抗凝。
- 比较有无凝血相关并发症患者的凝血与炎症参数,并用多变量逻辑模型评估这些标志物预测凝血相关并发症、危重症和死亡的效用。
主要发现
- 影像学确诊VTE率为4.8%(95%CI 2.9-7.3),总体血栓并发症率为9.5%(95%CI 6.8-12.8)。
- 总体出血率为4.8%(95%CI 2.9-7.3),大出血率为2.3%(95%CI 1.0-4.2)。
- 危重症患者中影像学确诊VTE率为7.6%(95%CI 3.9-13.3),大出血率为5.6%(95%CI 2.4-10.7)。
- 初始D-二聚体>2500 ng/mL预测住院期间血栓并发症调整OR 6.79(95%CI 2.39-19.30),出血调整OR 3.56(95%CI 1.01-12.66)。
- 初始血小板计数>450×10^9/L(调整OR 3.56,95%CI 1.27-9.97)、CRP>100 mg/L(调整OR 2.71,95%CI 1.26-5.86)、ESR>40 mm/h(调整OR 2.64,95%CI 1.07-6.51)预测住院期间血栓形成。
关键数值与推荐
- 血栓并发症患者ESR、CRP、纤维蛋白原、铁蛋白和降钙素原高于无血栓并发症患者。
- DIC、临床相关血小板减少和纤维蛋白原降低少见,且与明显出血表现相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with coronavirus disease 2019 (COVID-19) have elevated D-dimer levels. Early reports describe high venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) rates, but data are limited. This multicenter retrospective study describes the rate and severity of hemostatic and thrombotic complications of 400 hospital-admitted COVID-19 patients (144 critically ill) primarily receiving standard-dose prophylactic anticoagulation. Coagulation and inflammatory parameters were compared between patients with and without coagulation-associated complications. Multivariable logistic models examined the utility of these markers in predicting coagulation-associated complications, critical illness, and death. The radiographically confirmed VTE rate was 4.8% (95% confidence interval [CI], 2.9-7.3), and the overall thrombotic complication rate was 9.5% (95% CI, 6.8-12.8). The overall and major bleeding rates were 4.8% (95% CI, 2.9-7.3) and 2.3% (95% CI, 1.0-4.2), respectively. In the critically ill, radiographically confirmed VTE and major bleeding rates were 7.6% (95% CI, 3.9-13.3) and 5.6% (95% CI, 2.4-10.7), respectively. Elevated D-dimer at initial presentation was predictive of coagulation-associated complications during hospitalization (D-dimer >2500 ng/mL, adjusted odds ratio [OR] for thrombosis, 6.79 [95% CI, 2.39-19.30]; adjusted OR for bleeding, 3.56 [95% CI, 1.01-12.66]), critical illness, and death. Additional markers at initial presentation predictive of thrombosis during hospitalization included platelet count >450 × 109/L (adjusted OR, 3.56 [95% CI, 1.27-9.97]), C-reactive protein (CRP) >100 mg/L (adjusted OR, 2.71 [95% CI, 1.26-5.86]), and erythrocyte sedimentation rate (ESR) >40 mm/h (adjusted OR, 2.64 [95% CI, 1.07-6.51]). ESR, CRP, fibrinogen, ferritin, and procalcitonin were higher in patients with thrombotic complications than in those without. DIC, clinically relevant thrombocytopenia, and reduced fibrinogen were rare and were associated with significant bleeding manifestations. Given the observed bleeding rates, randomized trials are needed to determine any potential benefit of intensified anticoagulant prophylaxis in COVID-19 patients.
引用
- Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020. PMID: 32492712. doi:10.1182/blood.2020006520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。